Quick answer 30 sec
Pregnancy often means deciding whether to continue ADHD medication. Large register studies have been broadly reassuring about major birth defects with the most-used medications, though some studies suggest small increases in certain risks, such as preterm birth. Stopping treatment has its own risks too. This is a decision to make with a clinician who knows you.
What this can feel like
Lived experience
You’re asked to weigh risks nobody can quite quantify for you.
You stop your medication and suddenly everything — work, appointments, the house — gets harder, right when there’s more to organise than ever.
After the birth, the lack of sleep and structure hits in a way nobody warned you about.
A composite of what people describe — not a checklist, not a test. ADHD, or just being human?
What we know
Promising and growing, but incomplete: several consistent studies, often small or without a meta-analysis. Could change. What these labels mean A meta-analysis of 10 observational studies found no significant increase in congenital anomalies or miscarriage with methylphenidate or atomoxetine in pregnancy.
di Giacomo et al. 2024
- Meta-analysis di Giacomo E, Confalonieri V, Tofani F, Clerici M (2024). Methylphenidate and atomoxetine in pregnancy and possible adverse fetal outcomes: a systematic review and meta-analysis. JAMA Network Open, 7(11), e2443648. Open source ↗10 observational studies; no significant increase in congenital anomalies or miscarriage. A later correction adjusted estimates without changing conclusions.
Promising and growing, but incomplete: several consistent studies, often small or without a meta-analysis. Could change. What these labels mean A large Swedish register study, combined with a meta-analysis, examined whether exposure in the womb is linked to later neurodevelopmental conditions in children.
Swedish register study 2025
- Cohort / register study See original article (2025). In utero exposure to methylphenidate, amphetamines and atomoxetine and offspring neurodevelopmental disorders: a population-based cohort study and meta-analysis. Molecular Psychiatry. Open source ↗Register data from Sweden, combined with a meta-analysis.
Promising and growing, but incomplete: several consistent studies, often small or without a meta-analysis. Could change. What these labels mean Specialist consensus recommends that decisions about ADHD medication in pregnancy be made individually, weighing the risks of treatment against the risks of stopping.
Kooij et al. 2019
- Consensus statement Kooij JJS, Bijlenga D, Salerno L, et al. (2019). Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European Psychiatry, 56, 14–34. Open source ↗Notes the lack of research on sex and gender differences.
What the evidence suggests
Few or small studies, non-clinical samples, or evidence borrowed from other groups. Treat it as a hypothesis. What these labels mean Some studies report a small increase in some pregnancy outcomes (such as preterm birth and preeclampsia) with stimulant exposure; it is hard to separate the medication’s effect from ADHD itself.
Cohen et al. 2017
- Cohort / register study Cohen JM, Hernández-Díaz S, Bateman BT, et al. (2017). Placental complications associated with psychostimulant use in pregnancy. Obstetrics & Gynecology, 130(6), 1192–1201. Open source ↗US Medicaid cohort; small increases in preeclampsia and preterm birth with stimulant use; confounding by indication possible.
Few or small studies, non-clinical samples, or evidence borrowed from other groups. Treat it as a hypothesis. What these labels mean Women with ADHD may be at higher risk of postpartum depression.
Dorani et al. 2021
- Cross-sectional study Dorani F, et al. (incl. Kooij JJS) (2021). Prevalence of hormone-related mood disorder symptoms in women with ADHD. Journal of Psychiatric Research, 133, 10–15. Open source ↗209 women with ADHD; compared with general-population figures.
What we don’t know yet
- Long-term effects of prenatal medication exposure on children, beyond early childhood.
- How ADHD symptoms change across pregnancy and the postpartum period.
- Safety data for breastfeeding with ADHD medication is limited.
What research is needed
- Studies of ADHD symptoms (not just medication safety) across pregnancy and postpartum.
- Research on support for parents with ADHD in the first year.
What you can do with this
- If you’re planning a pregnancy, raise medication early with your prescriber — before, not after, stopping.
- Build external structure for the postpartum period in advance: shared calendars, checklists, and people who can hold some of the load.
Amorce never recommends medication, doses or contraception. Those decisions belong with a clinician who knows you.
What these labels mean
Sources 5
- Meta-analysis di Giacomo E, Confalonieri V, Tofani F, Clerici M (2024). Methylphenidate and atomoxetine in pregnancy and possible adverse fetal outcomes: a systematic review and meta-analysis. JAMA Network Open, 7(11), e2443648. Open source ↗10 observational studies; no significant increase in congenital anomalies or miscarriage. A later correction adjusted estimates without changing conclusions.
- Cohort / register study See original article (2025). In utero exposure to methylphenidate, amphetamines and atomoxetine and offspring neurodevelopmental disorders: a population-based cohort study and meta-analysis. Molecular Psychiatry. Open source ↗Register data from Sweden, combined with a meta-analysis.
- Clinical guideline National Institute for Health and Care Excellence (2018). Attention deficit hyperactivity disorder: diagnosis and management (NG87), updated 2019. NICE guideline. Open source ↗UK clinical guideline.
- Consensus statement Kooij JJS, Bijlenga D, Salerno L, et al. (2019). Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European Psychiatry, 56, 14–34. Open source ↗Notes the lack of research on sex and gender differences.
- Cross-sectional study Dorani F, et al. (incl. Kooij JJS) (2021). Prevalence of hormone-related mood disorder symptoms in women with ADHD. Journal of Psychiatric Research, 133, 10–15. Open source ↗209 women with ADHD; compared with general-population figures.
Written: 2026-09 · Written from a structured literature review by a non-professional · Not yet reviewed by a clinician